Shilpa Biologicals Pvt. Ltd. (SBPL) has introduced PartnerPower Platform, a proprietary digital transparency solution designed to provide global sponsors with continuous, real-time visibility across biologics development and manufacturing activities. Announced on 22 June 2026 from Dharwad, India, the platform is intended to give biopharmaceutical innovators uninterrupted access to project information, enabling them to monitor progress and operational status at any time and from any location. By moving beyond conventional periodic reporting models, the system creates a live and collaborative environment that offers immediate insight into development and manufacturing programs.
Built as a unified digital “data fabric,” the platform delivers direct visibility into process development laboratories and GMP manufacturing operations as data is generated. It connects information from research and development, analytical development, and manufacturing functions, supporting improved coordination between sponsors and operational teams. Through this integrated framework, PartnerPower Platform is designed to facilitate faster decision-making while helping streamline technology transfer activities throughout the product lifecycle. The launch forms part of Shilpa Biologicals’ broader effort to strengthen the CDMO experience through a more integrated and partnership-focused operating model.
Data integrity and sponsor confidentiality were incorporated as foundational elements during the platform’s development. The technology has also been aligned with the expectations of global regulatory agencies, including the US FDA, EMA, and PMDA, supporting a continuous state of audit readiness. Commenting on the launch, Madhav Bhutada, Director, Shilpa Biologicals, said: “With PartnerPowerTM, we are setting a new global benchmark for what transparency in a CDMO partnership should look like. It allows our sponsors to innovate with complete confidence, knowing that every data point, every decision, and milestone is visible to them in real time.”
The latest launch complements the company’s ongoing investments in biologics capabilities. These include dedicated bioconjugation suites for Antibody-Drug Conjugates (ADCs), one of the world’s largest microbial sites, and a commercial mAbs facility. Shilpa Biologicals will also be present at BIO San Diego’26, where visitors can meet the team at booth no. 3351.
